{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:17:42Z","timestamp":1790615862818,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01CA151610"],"award-info":[{"award-number":["2R01CA151610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA280458"],"award-info":[{"award-number":["R21CA280458"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Investigation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clnves.2026.100087","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:23:22Z","timestamp":1784971402000},"page":"100087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy"],"prefix":"10.1016","volume":"2","author":[{"given":"Linrong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnves.2026.100087_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.clnves.2026.100087_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.clnves.2026.100087_bib3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.clnves.2026.100087_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"L\u00f3pez de S\u00e1","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.clnves.2026.100087_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.clnves.2026.100087_bib6","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clnves.2026.100087_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12967-025-07450-x","article-title":"Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment","volume":"24","author":"Li","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.clnves.2026.100087_bib8","article-title":"Single protein encapsulated doxorubicin as an efficacious anticancer therapeutic","volume":"3","author":"Yu","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.clnves.2026.100087_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/cancers17050881","article-title":"Targeted treatment of sarcomas by single protein encapsulated doxorubicin with undetectable cardiotoxicity and superior efficacy","volume":"17","author":"Yu","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.clnves.2026.100087_bib10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-023-04778-0","article-title":"Single protein encapsulated SN38 for tumor-targeting treatment","volume":"21","author":"Yu","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["Cell Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305053802600027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305053802600027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:33:48Z","timestamp":1790613228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305053802600027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S305053802600027X"],"URL":"https:\/\/doi.org\/10.1016\/j.clnves.2026.100087","relation":{},"ISSN":["3050-5380"],"issn-type":[{"value":"3050-5380","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cell Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnves.2026.100087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100087"}}